Research graph
References from Coordinated cellular programmes distinguish responses to neoadjuvant PD-L1 blockade and potentiate combinatorial immunotherapy in ESCC. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21834
10.3322/caac.21834 · External reference
10.3322/caac.21338
10.3322/caac.21338 · External reference
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010
10.1016/j.ejca.2020.08.002 · 2020 · External reference
10.1038/s41586-022-05368-8
10.1038/s41586-022-05368-8 · External reference
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity
10.1038/s43018-021-00234-4 · 2021 · External reference
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
10.1016/s1470-2045(23)00108-0 · 2023 · External reference
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
10.1136/bmj-2021-068714 · 2022 · External reference
10.1056/nejmoa2111380
10.1056/nejmoa2111380 · External reference
10.1186/s12943-024-02023-w
10.1186/s12943-024-02023-w · External reference
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
10.3390/molecules24061190 · 2019 · External reference
10.7150/jca.57334
10.7150/jca.57334 · External reference
Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials
10.1016/j.medj.2025.100669 · 2025 · External reference
10.1093/annonc/mdw168
10.1093/annonc/mdw168 · External reference
10.1016/j.ccell.2022.02.007
10.1016/j.ccell.2022.02.007 · External reference
10.1001/jama.2021.12836
10.1001/jama.2021.12836 · External reference
10.1016/j.ccell.2023.09.011
10.1016/j.ccell.2023.09.011 · External reference
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
10.1038/s41591-023-02469-3 · 2023 · External reference
10.1038/s41587-021-01139-4
10.1038/s41587-021-01139-4 · External reference
10.1016/j.ccell.2023.03.001
10.1016/j.ccell.2023.03.001 · External reference
Hypoxia-Induced Senescent Fibroblasts Secrete IGF1 to Promote Cancer Stemness in Esophageal Squamous Cell Carcinoma
10.1158/0008-5472.can-24-1185 · 2025 · External reference
10.1016/j.cell.2022.03.033
10.1016/j.cell.2022.03.033 · External reference
10.1002/jcb.24228
10.1002/jcb.24228 · External reference
10.1038/s41419-021-04116-6
10.1038/s41419-021-04116-6 · External reference
10.1146/annurev-immunol-090222-110914
10.1146/annurev-immunol-090222-110914 · External reference
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms
10.1038/s41587-024-02232-0 · 2025 · External reference
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade
10.1038/s43018-022-00433-7 · 2022 · External reference
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy
10.1172/jci.insight.122467 · 2018 · External reference
Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance
10.1186/s13045-025-01722-1 · 2025 · External reference
10.1093/intimm/dxaa053
10.1093/intimm/dxaa053 · External reference
10.1016/j.cell.2024.06.038
10.1016/j.cell.2024.06.038 · External reference
Related Mechanisms of Antibody Somatic Hypermutation and Class Switch Recombination
2015 · External reference
Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy
10.1002/advs.202401061 · 2024 · External reference
10.1038/s41586-022-04801-2
10.1038/s41586-022-04801-2 · External reference
Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism
10.1016/j.xcrm.2024.101400 · 2024 · External reference
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
10.1016/j.cell.2025.03.018 · 2025 · External reference
10.1016/j.ccell.2025.02.026
10.1016/j.ccell.2025.02.026 · External reference
10.1038/s41591-018-0057-z
10.1038/s41591-018-0057-z · External reference
10.1038/s41467-024-52977-0
10.1038/s41467-024-52977-0 · External reference
10.1038/s41586-023-05771-9
10.1038/s41586-023-05771-9 · External reference
10.1016/j.ccell.2024.04.011
10.1016/j.ccell.2024.04.011 · External reference
10.1016/j.cell.2024.07.016
10.1016/j.cell.2024.07.016 · External reference
10.1016/j.cell.2024.06.036
10.1016/j.cell.2024.06.036 · External reference
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
10.1038/s41591-024-02877-z · 2024 · External reference
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
10.1186/s13045-025-01666-6 · 2025 · External reference
10.1158/1078-0432.ccr-19-3548
10.1158/1078-0432.ccr-19-3548 · External reference
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
10.1016/j.ymthe.2022.05.003 · 2022 · External reference
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
10.1080/2162402x.2021.1943180 · 2021 · External reference
10.1001/jama.2021.12836
10.1001/jama.2021.12836 · ExternalCitation · doi-reference
Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy
10.1002/advs.202401061 · ExternalCitation · doi-reference
10.1002/jcb.24228
10.1002/jcb.24228 · ExternalCitation · doi-reference
10.1016/j.ccell.2022.02.007
10.1016/j.ccell.2022.02.007 · ExternalCitation · doi-reference
10.1016/j.ccell.2023.03.001
10.1016/j.ccell.2023.03.001 · ExternalCitation · doi-reference
10.1016/j.ccell.2023.09.011
10.1016/j.ccell.2023.09.011 · ExternalCitation · doi-reference
10.1016/j.ccell.2024.04.011
10.1016/j.ccell.2024.04.011 · ExternalCitation · doi-reference
10.1016/j.ccell.2025.02.026
10.1016/j.ccell.2025.02.026 · ExternalCitation · doi-reference
10.1016/j.cell.2022.03.033
10.1016/j.cell.2022.03.033 · ExternalCitation · doi-reference
10.1016/j.cell.2024.06.036
10.1016/j.cell.2024.06.036 · ExternalCitation · doi-reference
10.1016/j.cell.2024.06.038
10.1016/j.cell.2024.06.038 · ExternalCitation · doi-reference
10.1016/j.cell.2024.07.016
10.1016/j.cell.2024.07.016 · ExternalCitation · doi-reference
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
10.1016/j.cell.2025.03.018 · ExternalCitation · doi-reference
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010
10.1016/j.ejca.2020.08.002 · ExternalCitation · doi-reference
Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials
10.1016/j.medj.2025.100669 · ExternalCitation · doi-reference
Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism
10.1016/j.xcrm.2024.101400 · ExternalCitation · doi-reference
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
10.1016/j.ymthe.2022.05.003 · ExternalCitation · doi-reference
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
10.1016/s1470-2045(23)00108-0 · ExternalCitation · doi-reference
10.1038/s41419-021-04116-6
10.1038/s41419-021-04116-6 · ExternalCitation · doi-reference
10.1038/s41467-024-52977-0
10.1038/s41467-024-52977-0 · ExternalCitation · doi-reference
10.1038/s41586-022-04801-2
10.1038/s41586-022-04801-2 · ExternalCitation · doi-reference
10.1038/s41586-022-05368-8
10.1038/s41586-022-05368-8 · ExternalCitation · doi-reference
10.1038/s41586-023-05771-9
10.1038/s41586-023-05771-9 · ExternalCitation · doi-reference
10.1038/s41587-021-01139-4
10.1038/s41587-021-01139-4 · ExternalCitation · doi-reference
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms
10.1038/s41587-024-02232-0 · ExternalCitation · doi-reference
10.1038/s41591-018-0057-z
10.1038/s41591-018-0057-z · ExternalCitation · doi-reference
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
10.1038/s41591-023-02469-3 · ExternalCitation · doi-reference
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
10.1038/s41591-024-02877-z · ExternalCitation · doi-reference
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity
10.1038/s43018-021-00234-4 · ExternalCitation · doi-reference
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade
10.1038/s43018-022-00433-7 · ExternalCitation · doi-reference
10.1056/nejmoa2111380
10.1056/nejmoa2111380 · ExternalCitation · doi-reference
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
10.1080/2162402x.2021.1943180 · ExternalCitation · doi-reference
10.1093/annonc/mdw168
10.1093/annonc/mdw168 · ExternalCitation · doi-reference
10.1093/intimm/dxaa053
10.1093/intimm/dxaa053 · ExternalCitation · doi-reference
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
10.1136/bmj-2021-068714 · ExternalCitation · doi-reference
10.1146/annurev-immunol-090222-110914
10.1146/annurev-immunol-090222-110914 · ExternalCitation · doi-reference
Hypoxia-Induced Senescent Fibroblasts Secrete IGF1 to Promote Cancer Stemness in Esophageal Squamous Cell Carcinoma
10.1158/0008-5472.can-24-1185 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-19-3548
10.1158/1078-0432.ccr-19-3548 · ExternalCitation · doi-reference
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy
10.1172/jci.insight.122467 · ExternalCitation · doi-reference
10.1186/s12943-024-02023-w
10.1186/s12943-024-02023-w · ExternalCitation · doi-reference
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
10.1186/s13045-025-01666-6 · ExternalCitation · doi-reference
Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance
10.1186/s13045-025-01722-1 · ExternalCitation · doi-reference
10.3322/caac.21338
10.3322/caac.21338 · ExternalCitation · doi-reference
10.3322/caac.21834
10.3322/caac.21834 · ExternalCitation · doi-reference
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
10.3390/molecules24061190 · ExternalCitation · doi-reference
10.7150/jca.57334
10.7150/jca.57334 · ExternalCitation · doi-reference
